THE PROGNOSTIC VALUE OF NEUTROPHIL TO LYMPHOCYTE RATIO IN ACUTE PANCREATITIS

Atika Budhy Setyani¹, Hening Tirta Kusumawardani², Michael Dwinata³

Present in:

International Conference of the Korean Pancreatobiliary Association 2020 (IC-KPBA 2020)

¹Emergency Medicine, Cempaka Putih General Hospital, Jakarta, Indonesia ²Critical Care, Mintohardjo Naval Hospital, Jakarta, Indonesia ³Internal Medicine, Depati Hamzah General Hospital, Pangkal Pinang, Indonesia



IC-KPBA²⁰20

International Conference of the Korean Pancreatobiliary Association 2020

"Multidisciplinary Perspectives on Pancreatobiliary Medicine

August 7 (Fri) ~ 8 (Sat), 2020 Conrad Seoul, Korea

COI Disclosure

Atika Budhy Setyani

The authors have no conflicts of interest to disclose.

BACKGROUND

- Acute pancreatitis (AP) is characterized by local and systemic inflammation, which is observed clinically from no systemic signs through the systemic inflammatory response syndrome (SIRS), organ failure (OF), persistent organ failure (POF), and death¹.
- Neutrophil to lymphocyte ratio (NLR), a simple, easily calculated systemic inflammation-based score, has been generally investigated in a variety of disease states, including inflammatory², cardiovascular³, and neoplastic conditions⁴.
- However, no meta-analysis has investigated the possible relationship between NLR and AP.

 1Banks PA, Bollen TL, et, al. Gut 2013;62:102–1

¹Banks PA, Bollen TL, et, al. Gut 2013;62:102–11. ²de Jager CP, et al. Crit Care 2010;14:R192

³Park JJ, et al. Am J Cardiol 2013;111:636–42.

⁴Picher M, et al. Br J Cancer2013;108:901–7.

OBJECTIVE

We aimed to investigate the prognostic value of NLR in predicting mortality and severity among acute pancreatitis patients.

METHOD

A comprehensive search was conducted to identify all eligible studies \rightarrow assessed the association of NLR and in acute pancreatitis published until January 2020

Databases:

- Pubmed
- Google Scholar
- Proquest
- Science Direct
- Clinical Key
- Cochrane



Revman 5.3, Random Effect or Fix Effect based on heterogeneity test for relative risk (RR) with Confidence Intervals (95% CI)

METHOD




Figure 1. Flow diagram of studies selection

RESULT

| | | | Odds Ratio | Odds Ratio |
|-------------------|---|--|--------------------|-------------------|
| Study or Subgroup | log[Odds Ratio] S | SE Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI |
| Li 2016 | 0.38049 0.3672 | 27 0.4% | 1.46 [0.71, 3.01] | <u></u> |
| Park 2019 | 0.13366 0.0236 | 35 97.4% | 1.14 [1.09, 1.20] | |
| Wang 2017 | 1.9036 0.8140 | J7 0.1% | 6.71 [1.36, 33.09] | |
| Zhang 2016 | 0.31481 0.1598 | 35 2.1% | 1.37 [1.00, 1.87] | - |
| Total (95% CI) | | 100.0% | 1.15 [1.10, 1.20] | |
| <u> </u> | : 6.39, df = 3 (P = 0.09); I² = : Z = 6.00 (P < 0.00001) | 0.05 0.2 1 5 20 Decreased Risk Increased Risk | | |

| | | | Odds Ratio | Odds Ratio |
|---|---|--|--------------------|-------------------|
| Study or Subgroup | log[Odds Ratio] SE | E Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI |
| Azab 2011 | 0.76779 0.3442 | 2 19.1% | 2.15 [1.10, 4.23] | |
| O'Connell 2018 | 2.09642 1.04055 | 5 2.1% | 8.14 [1.06, 62.54] | <u> </u> |
| Zhang 2016 | 0.36464 0.16928 | 3 78.8% | 1.44 [1.03, 2.01] | |
| Total (95% CI) | | 100.0% | 1.61 [1.20, 2.16] | • |
| Heterogeneity: Chi² = Test for overall effect: | 3.58, df = 2 (P = 0.17); l² = 4 : Z = 3.18 (P = 0.001) | 0.01 0.1 1 10 100 Decreased Risk Increased Risk | | |

Figure 2. Pooled estimation of NLR in prediction of severe AP (above) and ICU admission (below) among AP patients

RESULT

| | | | Odds Ratio | Odds Ratio |
|-------------------|---|-----------------------|--------------------|---|
| Study or Subgroup | log[Odds Ratio] S | E Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI |
| Li 2016 | 1.5531 0.54 | 4 41.5% | 4.73 [1.63, 13.73] | |
| Zhang 2016 | 1.0116 0.458 | 3 58.5% | 2.75 [1.12, 6.76] | |
| - | 0.58, df= 1 (P= 0.45); l²= Z= 3.53 (P= 0.0004) | 100.0% : 0% | 3.44 [1.73, 6.85] | 0.01 0.1 1 10 100 Decreased Risk Increased Risk |

Figure 3. Pooled estimation of NLR in prediction of mortality among AP patients

| | Severe | | | Mild | | | Mean Difference | | Mean Difference | | | |
|---|--------|--------|-------|-------|---------|-------|-----------------|--|--|-------------------|---------|---|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | | IV, Random, 95% C | :I | |
| Gulen 2015 | 9.99 | 6.6963 | 14 | 5.77 | 3.77037 | 308 | 22.3% | 4.22 [0.69, 7.75] | | - | | |
| Li 2016 | 25 | 13 | 31 | 10.47 | 16.9 | 328 | 18.4% | 14.53 [9.60, 19.46] | | - | | |
| Orak 2016 | 24.58 | 16.92 | 16 | 11.45 | 11.38 | 478 | 10.9% | 13.13 [4.78, 21.48] | | - | | |
| Zhang 2016 | 23.81 | 15.09 | 58 | 12.19 | 10.59 | 918 | 21.1% | 11.62 [7.68, 15.56] | | - | | ļ |
| Zhou 2019 | 13.64 | 2.9 | 14 | 6.65 | 4.93077 | 392 | 27.2% | 6.99 [5.39, 8.59] | | • | | |
| Total (95% CI) | | | 133 | | | 2424 | 100.0% | 9.41 [5.90, 12.91] | | • | | |
| Heterogeneity: Tau² = 11.09; Chi² = 17.27, df = 4 (P = 0.002); l² = 77% | | | | | | | | | | 50 10 | JU H | |
| Test for overall effect: $Z = 5.26$ (P < 0.00001) | | | | | | | | .00 | Severe MIId | | • | |

Figure 4. Pooled estimation of weighted mean difference of NLR between mortality and survived patients with acute pancreatitis.

RESULT

| | Severe Mild Mean Difference | | | | | | Mean Difference | | |
|--|-----------------------------|------------|-------|-------|-----------|--------|-----------------|----------------------|-------------------------------|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| Abayli 2018 | 16.36 | 11.96 | 53 | 8.56 | 9.68 | 382 | 5.2% | 7.80 [4.44, 11.16] | |
| Alimujiang 2015 | 14.64 | 4.65 | 44 | 7.12 | 2.75 | 62 | 7.2% | 7.52 [5.98, 9.06] | - |
| Azab 2011 | 11.4 | 7.11 | 22 | 7.3 | 7.34 | 261 | 5.5% | 4.10 [1.00, 7.20] | - |
| Cho 2018 | 9.8 | 8.8 | 19 | 8.7 | 8.3 | 90 | 4.3% | 1.10 [-3.21, 5.41] | + |
| Cho-2 2018 | 32.4 | 30.9 | 6 | 17.1 | 17.4 | 128 | 0.3% | 15.30 [-9.61, 40.21] | |
| Huang 2019 | 12.24 | 8.37 | 45 | 8.32 | 7.24 | 223 | 6.0% | 3.92 [1.30, 6.54] | |
| Jeon 2017 | 6.71 | 5.71111 | 70 | 4.47 | 4.31111 | 420 | 7.3% | 2.24 [0.84, 3.64] | - |
| Kokulu 2018 | 16 | 13.81 | 19 | 5.01 | 5.1 | 81 | 2.8% | 10.99 [4.68, 17.30] | |
| Li 2016 | 19.65 | 8.35 | 86 | 8.46 | 8.945 | 197 | 6.5% | 11.19 [9.03, 13.35] | - |
| Orak 2016 | 13.85 | 13.17 | 194 | 10.6 | 10.66 | 300 | 6.5% | 3.25 [1.04, 5.46] | |
| Park 2019 | 14.85 | 10.9852 | 52 | 5.7 | 5.12593 | 620 | 5.6% | 9.15 [6.14, 12.16] | - |
| Qi 2017 | 12.43 | 7.92 | 92 | 7.63 | 4.4 | 104 | 6.9% | 4.80 [2.97, 6.63] | - |
| Raghavan 2019 | 9.1 | 0.88889 | 8 | 5.4 | 0.37037 | 22 | 7.8% | 3.70 [3.06, 4.34] | - |
| Shen 2015 | 15.5 | 8.74074 | 30 | 10.9 | 7.77778 | 123 | 5.2% | 4.60 [1.18, 8.02] | |
| Suppiah 2013 | 18.15 | 9.03704 | 22 | 13.22 | 10.963 | 124 | 4.3% | 4.93 [0.69, 9.17] | |
| Wang 2017 | 14.6 | 5.9 | 10 | 6.9 | 3.9 | 100 | 4.8% | 7.70 [3.96, 11.44] | |
| Zhang 2016 | 19.89 | 14.26 | 223 | 10.8 | 9.22 | 551 | 6.7% | 9.09 [7.07, 11.11] | - |
| Zhou 2019 | 10.7 | 5.0889 | 56 | 5.54 | 4.32593 | 237 | 7.2% | 5.16 [3.72, 6.60] | - |
| Total (95% CI) | | | 1051 | | | 4025 | 100.0% | 5.84 [4.53, 7.15] | • |
| Heterogeneity: Tou³ = 5.63: Chi² = 110.60. df = 17.7P ≤ 0.00001): i² = 95% | | | | | | | | | |
| Test for overall effect: 2 | | | - | | 0.00001/, | . – 55 | | | -20 -10 0 10 20 |
| 1002101 0701411 011002. | 0.70 | (i - 0.00t | 5517 | | | | | | Decreased Risk Increased Risk |

Figure 5. Pooled estimation of weighted mean difference of NLR between Severe Acute Pancretitis and Mild Acute Pancretitis.

CONCLUSION

Higher NLR was an independent predictor of SAP, ICU admission, and mortality. Therefore, the use of the potential role of NLR should be emphasized due to its affordability and accessibility in the low-resource setting.